The efficacy of chemotherapy in patients with high-grade metastatic colon cancer

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1495-1501

  Liu, Chia Jen ^a,b   Lin, Jen Kou ^b   Chen, Wei Shone ^b   Lin, Tzu Chen ^b   Yang, Shung Haur ^b   Jiang, Jeng Kai ^b   Chang, Shih Ching ^b   Lan, Yuan Tzu ^b   Yen, Chueh Chuan ^a,b   Tzeng, Cheng Hwai ^a,b   Wang, Hsei Wei ^b   Teng, Hao Wei ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Colon cancer; Histological grade; Irinotecan; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; COLON CANCER; DRUG EFFICACY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 83355163512     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11082     Document Type: Article

References (32)

1. Chen SP, Wu CC, Lin SZ, Rang JC, Su CC, Chen YL, et al.: Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. Am J Clin Oncol 2009; 32:122-6.
2. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37. (Pubitemid 41095086)
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7. (Pubitemid 30162806)
4. Giacchetti S, Perpoint B, Zidani R, Le BN, Faggiuolo R, Focan C, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47. (Pubitemid 30036347)
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30. (Pubitemid 41095110)
6. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-14. (Pubitemid 41079833)
7. Hospers GA, Schaapveld M, Nortier JW, Wils J, van BA, de Jong RS, et al.: Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Ann Oncol 2006; 17:443-9. (Pubitemid 43329581)
8. Kohne CH, van CE, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al.: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856-65. (Pubitemid 46223990)
9. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
10. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-806. (Pubitemid 41095169)
11. Newland RC, Dent OF, Lyttle MN, Chapuis PH, Bokey EL: Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 1994; 73:2076-82. (Pubitemid 24107961)
12. Benson AB, III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-19. (Pubitemid 41103700)
13. Engstrom PF, Arnoletti JP, Benson AB, III, Chen YJ, Choti MA, Cooper HS, et al.: NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 2009; 7:778-831.
14. Morris M, Platell C, de BB, McCaul K, Iacopetta B: Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93:866-71. (Pubitemid 44035260)
15. Robey-Cafferty SS, el-Naggar AK, Grignon DJ, Cleary KR, Ro JY: Histologic parameters and DNA ploidy as predictors of survival in stage B adenocarcinoma of colon and rectum. Mod Pathol 1990; 3:261-6.
16. de GA, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
17. O'Neil BH, Goldberg RM: Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008; 13:1074-83.
18. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-16.
19. Koo JH, Kin S, Wong C, Jalaludin B, Kneebone A, Connor SJ, et al.: Clinical and pathologic outcomes of colorectal cancer in a multi-ethnic population. Clin Gastroenterol Hepatol 2008; 6:1016-21.
20. Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM: Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg 2003; 90:205-14. (Pubitemid 36237896)
21. Blenkinsopp WK, Stewart-Brown S, Blesovsky L, Kearney G, Fielding LP: Histopathology reporting in large bowel cancer. J Clin Pathol 1981; 34:509-13. (Pubitemid 11063958)
22. Deans GT, Patterson CC, Parks TG, Spence RA, Heatley M, Moorehead RJ, et al.: Colorectal carcinoma: importance of clinical and pathological factors in survival. AnnRCollSurgEngl 1994; 76:59-64. (Pubitemid 24030549)
23. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F: Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 1998; 41:1033-49. (Pubitemid 28369295)
24. Bosch TM, Meijerman I, Beijnen JH, Schellens JH: Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006; 45:253-85. (Pubitemid 43327492)
25. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, et al.: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27:5519-28.
26. Furuta T: Pharmacogenomics in chemotherapy for GI tract cancer. J Gastroenterol 2009; 44:1016-25.
27. Heidemann J, Maaser C, Lugering A, Spahn TW, Zimmer KP, Herbst H, et al.: Expression of vascular cell adhesion molecule-1 (CD 106) in normal and neoplastic human esophageal squamous epithelium. Int J Oncol 2006; 28:77-85.
28. Koyama T, Nakamura T, Komoto C, Sakaeda T, Taniguchi M, Okamura N, et al.: MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull 2006; 29:1449-53.
29. Nguyen H, Tran A, Lipkin S, Fruehauf JP: Pharmacogenomics of colorectal cancer prevention and treatment. Cancer Invest 2006; 24:630-9. (Pubitemid 44422928)
30. Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A, et al.: VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci 2008; 5:80-6. (Pubitemid 351871010)
31. Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, et al.: Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 2006; 28:231-6.
32. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH: Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002; 41:65-74. (Pubitemid 34779683)